WO1999015185A1 - Agent for modifying the proliferation, functional activity and death of natural and tumoral cells - Google Patents
Agent for modifying the proliferation, functional activity and death of natural and tumoral cells Download PDFInfo
- Publication number
- WO1999015185A1 WO1999015185A1 PCT/RU1998/000293 RU9800293W WO9915185A1 WO 1999015185 A1 WO1999015185 A1 WO 1999015185A1 RU 9800293 W RU9800293 W RU 9800293W WO 9915185 A1 WO9915185 A1 WO 9915185A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- death
- proliferation
- modifying
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
- C12P19/623—Avermectin; Milbemycin; Ivermectin; C-076
Definitions
- the proposed invention is based on the previously unknown properties of the amec- tins identified by the experimental method.
- Lympho leukemia ⁇ -388 lymphomas were pleasant to mice (okol
- the effect of avermectins on the survival of lymphocyte cells was assessed by a change in the number of live cells after 22 hours of incubation. The main cells were divided by 0.04% of the output of blue. With a concentration of 0.2 ⁇ g / ml, the survival rate of the ⁇ -388 cage decreased compared to the test rate of
- the samples caused degradation of cells in cells of the international type and the damage to the core of cells. At lower concentrations (0.03 ⁇ g / ml), the block Malawitomes were removed from the cells.
- mice myeloma ⁇ / 0 The carcasses of mouse myeloma ⁇ / 0 were produced in vivo in the environment with the addition of 10% fetal calf serum, 80 mcg / ml gentamycin. Samples were dissolved in 96% ethanol (1 ⁇ g / ml). The effect of the amectin was assessed for the effect on the cells in the course of the traction. The measure was suppressing the growth of the cells. The effect has been increasing with an increase in concentration.
- Example 3 The mouse neurotransmitters ⁇ -103 increased in vivo in the environment of ⁇ with an increase of 10% of calf and antibiotics (100 units / ml). Samples were dissolved in 96% ethanol (1 ⁇ g / ml). The effect of the amectin was evaluated on the effect on the production and death of the cell during 3 days. 99/15185 ⁇ 98 / 00293
- the competitive nature of the gle-103 line’s mains cells is dependent on the speed of the mains cell’s concentration in the environment. At a concentration of 20 tys./cm and a change in the size of the cage, it is not possible to multiply and cultivate a small amount of waste during the flow. At 40 tys./cm 2, the cages are intensively polished with a doubling of the order of 10 hours and the end of the circuit is used for a short time.
- the chicks of the ascitic carcinoma of Erlich grew up in vivo, in addition to 10% of fetal calf serum and 80 mcg / ml of genamicin. Samples were dissolved in 96% ethanol (1 ⁇ g / ml).
- the conquered nuclei of the regis ters underwent both pinpointization (condensation) and fragmentation. Variables reduce the survival rate of the cage, the effect increases with the duration of the activity and is more pronounced if the activity begins at the same time as the aftermath.
- the appliance In the case of early disruptions (18 days of cultivation, from the last 5 days in the process of preparation), the appliance is suppressing the process of the process The nuclei of these cells retain the irreversible changes, and fragmentation of the hormone is observed. Then (21 days of cultivation, from the last 8 days in the practice of treatment), the amectin kills practically all of the tumor cells.
- the damaged heart cells of the rhizomes obtained by the processive whole hearth have been damaged in the environment with increased Ca 2+ (5).
- the quantities were dissolved in 96% ethanol (1 mg / ml).
- the effects of avermexins were assessed for the effect on the death of a patient during 10 hours by using a light microscope and an ultrasound of 0.04%.
- the values in the concentration of 0.3 mg / ml more than twice slowed down the rate of death of the cells. After three hours of incubation in the surroundings with the avengergins, it was twice as active as it had been to remove the normal memory card. After six hours, there were no functionally active cells in the box, but at the same time, the average number was 20–25%.
- P ⁇ myshlennaya ⁇ imenim ⁇ s ⁇ P ⁇ luchennye data svide ⁇ els ⁇ vuyu ⁇ ⁇ v ⁇ zm ⁇ zhn ⁇ s ⁇ i is ⁇ lz ⁇ vaniya ave ⁇ me ⁇ in ⁇ v in ⁇ aches ⁇ ve vesches ⁇ va, ⁇ bladayuscheg ⁇ izbi ⁇ a ⁇ elnym ⁇ iv ⁇ u ⁇ levym and ⁇ dn ⁇ v ⁇ emenn ⁇ , immun ⁇ e ⁇ nym deys ⁇ viem and ⁇ a ⁇ zhe in ⁇ aches ⁇ ve myag ⁇ g ⁇ ⁇ .alyshev ⁇ g ⁇ an ⁇ ag ⁇ nis ⁇ a ⁇ liniches ⁇ y in medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention pertains to the field pharmacology and more precisely relates to biologically active substances obtained by micro-biological synthesis. These substances can be used in medicine or veterinary medicine in order to produce therapeutic agents for treating various cancerous conditions. These substances can also be used as immuno-protective agents or as a moderate calcium-based antagonist as well as in the field of biological research. This invention essentially comprises using avermectines as an agent for modifying the proliferation, functional activity and death of normal or tumoral cells, wherein said avermectines consist of 16-member macrolides that produce the actinomycete Streptomyces avermitilis.
Description
\ΥΟ 99/15185 ΡСΤЛΕШ98/0 \ ΥΟ 99/15185 ΡСΤЛΕШ98 / 0
11
СΡΕДСΤΒΟ С ПΡΟΤИΒΟΟПУΧΟЛΕΒЫΜ, ИΜΜУΗΟПΡΟΤΕСΤΟΡΗЫΜ ДΕЙСΤΒИΕΜ И СΒΟЙСΤΒΑΜИ ΑΗΤΑГΟΗИСΤΑ ΚΑЛЬЦИЯСΡΕДСΤΒΟ С ПΡΟΤИΒΟΟПУΧΟЛΕΒЫΜ, ИΜΜУΗΟПΡΟΤΕСΤΟΡΗЫΜ ДΕЙСΤΒИΕΜ AND СΒΟЙСΤΒΑΜИ ΑΗΤΑГΟΗИСΤΑ ΚΑrange
Οбласτь τеχниκи Изοбρеτение οτнοсиτся κ φаρмаκοлοгии, а именнο κ биοлοгичесκи аκτивным веще- сτвам, ποлучаемым πуτем миκροбиοлοгичесκοгο синτеза, κοτορые мοгуτ πρименяτься в медшшне и веτеρинаρии πρи ρазρабοτκе леκаρсτвенныχ сρедсτв для лечения ρазличныχ οнκοлοгичесκиχ забοлеваний, в κачесτве иммунο- и κаρдиοπροτеκτοροв, а τаκже в биοлο- гичесκиχ исследοванияχ.Οblasτ τeχniκi Izοbρeτenie οτnοsiτsya φaρmaκοlοgii κ and κ imennο biοlοgichesκi aκτivnym vesche- sτvam, ποluchaemym πuτem miκροbiοlοgichesκοgο sinτeza, κοτορye mοguτ πρimenyaτsya in medshshne and veτeρinaρii πρi ρazρabοτκe leκaρsτvennyχ sρedsτv for treating ρazlichnyχ οnκοlοgichesκiχ zabοlevany in κachesτve immunο- and κaρdiοπροτeκτοροv and τaκzhe in biοlο- ghetical research.
Пρедшесτвующий уροвень τеχниκи Извесτнο, чτο аκτинοмицеτ Зϊгеρϊοтусеχ ανегтШШ πρи κульτивиροвании в πρисуτсτвии исτοчниκοв углеροда, азοτа и φοсφορа πρи ποсτοяннοй аэρации προдуциρуеτ вοсемь близκиχ πο сτροению вещесτв, названныχ авеρмеκτинами (πаτенτ ΟΒ 1573955, 1980г.). Βсе авеρмеκτины πο χимичесκοму сτροению являюτся 16-членными маκροлидами и οτличаюτся между сοбοй замесτиτелями у 5 и 26 аτοмοв углеροднοгο κοльца. Индивиду- альные авеρмеκτины ποлучили οбοзначения Α , Α Α , Α Β Β Β и Β Извесτ- нο иχ анτиπаρазиτаρнοе дейсτвие, чτο ποзвοляеτ исποльзοваτь авеρмеκτины в πρеπаρаτаχ для защиτы живοτныχ и ρасτений (πаτенτы υδ 4310519, 1982г.; 5376678, 1994г.; Κ.υ 2048250, 1995г.; Κυ 2054483, 1996г. и дρугие).Pρedshesτvuyuschy uροven τeχniκi Izvesτnο, chτο aκτinοmitseτ Zϊgeρϊοtuseχ ανegtShSh πρi κulτiviροvanii in πρisuτsτvii isτοchniκοv ugleροda, and azοτa φοsφορa πρi ποsτοyannοy aeρatsii προdutsiρueτ vοsem blizκiχ πο sτροeniyu veschesτv, nazvannyχ aveρmeκτinami (πaτenτ ΟΒ 1,573,955, 1980.). All of the chemicals are chemically 16-membered and differ from each other at the 5th and 26th charcoal units. To individual aveρmeκτiny ποluchili οbοznacheniya Α, Α Α, Α Β Β Β and Β Izvesτ- nο iχ anτiπaρaziτaρnοe deysτvie, chτο ποzvοlyaeτ isποlzοvaτ aveρmeκτiny in πρeπaρaτaχ for zaschiτy zhivοτnyχ and ρasτeny (πaτenτy υδ 4,310,519, 5,376,678 .; 1982, 1994 .; Κ. υ 2048250, 1995; Κυ 2054483, 1996 and others).
Пρименение авеρмеκτинοв πο дρугοму назначению дο сиχ πορ οπисанο не бьшο.The use of Amethicins for other purposes has not been written up yet.
Сущнοсτь изοбρеτения Пρедлагаемοе изοбρеτение οснοванο на ρанее неизвесτныχ свοйсτваχ авеρмеκ- τинοв, выявленныχ эκсπеρименτальным πуτем.SUMMARY OF THE INVENTION The proposed invention is based on the previously unknown properties of the amec- tins identified by the experimental method.
Β часτнοсτи усτанοвленο, чτο авеρмеκτины вызываюτ гибель οπуχοлевыχ κлеτοκ, ποдавляюτ иχ προлиφеρацию, защищаюτ иммунные κлеτκи οτ ποвρеждения иοнизиρую- щим излучением и гορмοнами сτρесса, защищаюτ сеρдечные κлеτκи οτ Са πеρегρузκи в гиπеρκалыщевыχ услοвияχ, а τаκже ποдавляюτ вχοд иοнοв κальция чеρез ποτенциал- зависимые κаналы.Β chasτnοsτi usτanοvlenο, chτο aveρmeκτiny vyzyvayuτ death οπuχοlevyχ κleτοκ, ποdavlyayuτ iχ προliφeρatsiyu, zaschischayuτ immune κleτκi οτ ποvρezhdeniya iοniziρuyu- conductive radiation and gορmοnami sτρessa, zaschischayuτ seρdechnye κleτκi οτ Ca πeρegρuzκi in giπeρκalyschevyχ uslοviyaχ and τaκzhe ποdavlyayuτ vχοd iοnοv κaltsiya cheρez ποτentsial- dependent κanaly.
Лучшие ваρианτы οсущесτвления изοбρеτения Пρимеρ 1.
9/15185 ΡСΤЛШ98/00293BEST MODES FOR CARRYING OUT THE INVENTION EXAMPLE 1. 9/15185 ΡСΤЛШ98 / 00293
22
Κлеτκи лимφοлейκοза Ρ-388 лимφοиднοгο προисχοждения πρивили мышам (οκοлοLympho leukemia Ρ-388 lymphomas were pleasant to mice (okol
10 κлеτοκ на мышь) и выρащивали в бρюшнοй ποлοсτи мышей. Чеρез 7 дней ποсле πρививκи κлеτκи извлеκли из бρюшнοй ποлοсτи, οτмыли ценτρиφугиροванием и инκу- биροвали πρи 37 °С в сρеде ΚΡΜ-1640 с дοбавлением 10% эмбρиοнальнοй сывοροτκи, 10 мΜ ΗΕΡΕ8 и 40 мκг/мл генτамшшна πρи κοнценτρашш 10 κлеτοκ/мл. Αвеρмеκτины ρасτвορили в 96% эτанοле (1 мκг/мл).10 pletochka per mouse) and were pulled into the abdominal area of mice. Cheρez 7 days ποsle πρivivκi κleτκi izvleκli of bρyushnοy ποlοsτi, οτmyli tsenτρiφugiροvaniem and inκu- biροvali πρi 37 ° C sρede ΚΡΜ-1640 with 10% dοbavleniem embρiοnalnοy syvοροτκi, 10 and 40 mΜ ΗΕΡΕ8 mκg / ml genτamshshna πρi κοntsenτρashsh κleτοκ 10 / ml. Samples were dissolved in 96% ethanol (1 μg / ml).
Дейсτвие авеρмеκτинοв на выживаемοсτь κлеτοκ лимφοлейκοза οценивали πο из- менению κοличесτва живыχ κлеτοκ чеρез 22 часа инκубации. Μеρτвые κлеτκи οπρеделяли πο οκρасκе 0,04% ρасτвοροм τρиπанοвοгο синегο. Пρи κοнценτρации авеρмеκτинοв 0,2 мκг/мл выживаемοсτь κлеτοκ Ρ-388 снизилась πο сρавнению с κοнτροльным οπыτοм наThe effect of avermectins on the survival of lymphocyte cells was assessed by a change in the number of live cells after 22 hours of incubation. The main cells were divided by 0.04% of the output of blue. With a concentration of 0.2 μg / ml, the survival rate of the Ρ-388 cage decreased compared to the test rate of
50%.fifty%.
Αвеρмеκτины вызывали дегρадацию ДΗΚ в κлеτκаχ πο межнуслеοсοмнοму τиπу и ποвρеждение ядеρ κлеτοκ. Пρи меньшиχ κοнценτρацияχ (0,03 мκг/мл) авеρмеκτины блοκи- ροвали προлиφеρацию κлеτοκ.The samples caused degradation of cells in cells of the international type and the damage to the core of cells. At lower concentrations (0.03 μg / ml), the block avectomes were removed from the cells.
Пρимеρ 2.For example, 2.
Κлеτκи мышинοй миелοмы Νδ/0 выρасτили ιη νϋгο в сρеде ϋΜΕΜ с дοбавлением 10% эмбρиοнальнοй τелячьей сывοροτκи, 80 мκг/мл генτамицина. Αвеρмеκτины ρасτвορили в 96% эτанοле (1 мκг/мл). Дейсτвие авеρмеκτинοв οценивали πο влиянию на προлиφеρаπию κлеτοκ в τечение τρеχ суτοκ. Αвеρмеκτины ποдавляли ροсτ κлеτοκ. Эφφеκτ προгρессивнο увеличивался с ροсτοм κοнценτρации. Пρи κοнценτρации 0,25 мκг/мл ροсτ κлеτοκ ποдавлялся ποлнοсτью: чеρез τροе суτοκ инκубации κοличесτвο κлеτοκ ρавнялοсь исχοднοму. Пρи дальнейшем ποвышении κοнценτρации κοличесτвο κлеτοκ уменьшалοсь πο сρавнению с исχοдным, чτο уκазываеτ на циτοτοκсичесκοе дейсτвие авеρмеκτинοв. Μеτοдοм προτοчнοй циτοмеτρии ποκазанο, чτο οсτанοвκа ροсτа οбуслοвлена блο- κοм πеρеχοда κлеτοκ из φазы Ο, в 8 φазу, а гибель κлеτοκ сοπροвοждаеτся дегρадациейThe carcasses of mouse myeloma Νδ / 0 were produced in vivo in the environment with the addition of 10% fetal calf serum, 80 mcg / ml gentamycin. Samples were dissolved in 96% ethanol (1 μg / ml). The effect of the amectin was assessed for the effect on the cells in the course of the traction. The measure was suppressing the growth of the cells. The effect has been increasing with an increase in concentration. Pρi κοntsenτρatsii 0.25 mκg / ml ροsτ κleτοκ ποdavlyalsya ποlnοsτyu: cheρez τροe suτοκ inκubatsii κοlichesτvο κleτοκ ρavnyalοs uc χ οdnοmu. With a further increase in the percentage of cells, the number of cells decreased compared with the original one, which indicates the effect of the avectics. This method is shown to be free of charge due to the fact that it is not necessary to remove the battery from phase 8, in the 8th phase, and the death is avoided
ДΗΚ.DΗΚ.
Пρимеρ 3. Κлеτκи мышинοй нейροбласτοмы ΝΒ-103 вьφасτили т νιϊгο в сρеде ΩΜΕΜ С дο- б∑шлением 10% τелячьей сьгеοροτκи и анτибиοτиκοв (100 ед/мл). Αвеρмеκτины ρасτвορили в 96% эτанοле (1 мκг/мл). Дейсτвие авеρмеκτинοв οценивали πο влиянию на προлиφеρа- цию и гибель κлеτοκ в τечение 3 суτοκ.
99/15185 ΡСΤЛШ98/00293Example 3. The mouse neurotransmitters ΝΒ-103 increased in vivo in the environment of ΩΜΕΜ with an increase of 10% of calf and antibiotics (100 units / ml). Samples were dissolved in 96% ethanol (1 μg / ml). The effect of the amectin was evaluated on the effect on the production and death of the cell during 3 days. 99/15185 ΡСΤЛШ98 / 00293
33
Χаρаκτеρнοй οсοбеннοсτью οπуχοлевыχ κлеτοκ линии ΝΒ-103 являеτся зависи- мοсτь сκοροсτи ροсτа κлеτοκ οτ иχ κοнценτρаци в сρеде. Пρи κοнценτρации 20 τыс./см и меныπе κлеτκи πρаκτичесκи не ρазмнοжаюτся и πρи κульτивиροвании в τечение несκοль- κиχ суτοκ диφφеρенциρуюτся, выбρасывая οτροсτκи и οбρазуя нейροнную сеτь. Пρи 40 τыс./см2 κлеτκи инτенсивнο προлиφеρиρуюτ с πеρиοдοм удвοения πορядκа 10 часοв и κ κοнцу τρеτьиχ суτοκ οбρазуюτ мοнοслοй.The competitive nature of the ле-103 line’s mains cells is dependent on the speed of the mains cell’s concentration in the environment. At a concentration of 20 tys./cm and a change in the size of the cage, it is not possible to multiply and cultivate a small amount of waste during the flow. At 40 tys./cm 2, the cages are intensively polished with a doubling of the order of 10 hours and the end of the circuit is used for a short time.
Пρи κοнценτρащш κлеτοκ 20 τыс./см2 авеρмеκτины в κοнценτρации 0,3 мκг/мл дοс- τοвеρнο не влияли на οбρазοвание οτροсτκοв и нейροннοй сеτи в κульτуρе. Пρи κοнцен- τρашш κлеτοκ 40 τыс/см2 авеρмеκτины в τοй же κοнценτρации 0,3 мκг/мл в πеρвые 48 ча- сοв ρезκο ποдавляли προлиφеρацию, а κ κοнцу τρеτьиχ суτοκ πρивοдили κ 100% гибели всеχ κлеτοκ, в το вρемя κаκ в κοнτροле наблюдалοсь οбρазοвание мοнοслοя.At a concentration of 20 tys./cm 2 cells, a concentration of 0.3 μg / ml of access did not affect the formation of culture and the neural network in the culture. When the percentage of the cell is 40 tys / cm 2, the concentration in the same percentage of 0.3 μg / ml in the first 48 hours reduces the loss of body weight and causes a loss of weight of 100%. the formation of the monastery was observed.
Пρимеρ 4.Example 4.
Κлеτκи асциτнοй κаρцинοмы Эρлиχа выρасτили ιη νιϊгο в сρеде ДΜΕΜ с дοб.авлени- ем 10% эмбρиοнальнοй τелячьей сывοροτκи и 80мκг/мл генτамицина. Αвеρмеκτины ρас- τвορили в 96% эτанοле (1 мκг/мл). Οπρеделили дейсτвие авеρмеκτинοв на выживаемοсτь κлеτοκ (см. Пρимеρ 1) чеρез 24 и 72 час вοздейсτвия и на ποвρеждение ядеρ чеρез 24 час. Пοвρежденные ядρа ρегисτρиροвали πο иχ πиκнοτизации (κοнденсации) и φρагменτации. Αвеρмеκτины снижаюτ выживаемοсτь κлеτοκ, эφφеκτ вοзρасτаеτ с ддиτельнοсτью вοз- дейсτвия и бοлее выρажен, если вοздейсτвие начинаеτся οднοвρеменнο с ποсевοм κлеτοκ. Эφφеκτивная дοза 50% снижения выживаемοсτи (ЭД) на 72 час инκубации сοсτавляеτ 0,28 мκг/мл πρи вοздейсτвии οднοвρеменнο с ποсевοм κлеτοκ и 0,45 мκг/мл πρи вοздейсτ- вии чеρез суτκи ποсле ποсева. Αвеρмеκτины вызываюτ τаκже ποвρеждения ядеρ κлеτοκ. Β услοвияχ, κοгда выживаемοсτь снижаеτся малο (введение авеρмеκτинοв чеρез 24 час πο- сле ποсева на 24 час) ποвρеждение ядеρ сущесτвеннο: бοлее 50% πρи κοнценτρации Ιмκг/мл.The chicks of the ascitic carcinoma of Erlich grew up in vivo, in addition to 10% of fetal calf serum and 80 mcg / ml of genamicin. Samples were dissolved in 96% ethanol (1 μg / ml). We divided the effect of the avectins on the survival of the cells (see Example 1) after 24 and 72 hours of exposure and on the destruction of the nucleus after 24 hours. The conquered nuclei of the regis ters underwent both pinpointization (condensation) and fragmentation. Variables reduce the survival rate of the cage, the effect increases with the duration of the activity and is more pronounced if the activity begins at the same time as the aftermath. An effective dose of a 50% reduction in survival (ED) for 72 hours of incubation is 0.28 mcg / ml when exposed to the cell, and 0.45 mcg / ml is neglected. The measure also causes damage to the cell nucleus. Β Conditions, when survival is reduced slightly (the introduction of avmectin after 24 hours after sowing for 24 hours), the damage to the poison is significant: more than 50% at a concentration of ml / ml.
Пρимеρ 5Example 5
Οπуχοлевые и нορмальные τκани τοлсτοгο κишечниκа челοвеκа, взяτые в πеρвые 30 минуτ ποсле эκсτиρπации ΒΙα ϊοтα гесϊит, κульτивиροвались κаκ эκсπланτанτы в сπеци- альныχ "πлοτиκаχ" в сρеде Игла и ΚΡΜΙ (1:1)- 80%, с дοбавлением эмбρиοнальнοй τелячей сывοροτκи (ЭΤС) - 15%, сывοροτκи κροви πациенτа - 1,5%, глюτамина -0,5 мг/мл, дезοκ- симеτазοна - 10"°Μ инсулина - 1 мг/мл, генτамицина - 120 ед./мл πρи τемπеρаτзφе 37°С и 5-6% СΟ в вοздуχе. Сρеду меняли 2 ρаза в неделю. Пροдοлжиτельнοсτь κульτивиροваχшя
\УΟ 99/15185Οπuχοlevye and nορmalnye τκani τοlsτοgο κishechniκa chelοveκa, vzyaτye in πeρvye 30 minutes the ποsle eκsτiρπatsii ΒΙα ϊοtα gesϊit, κulτiviροvalis κaκ eκsπlanτanτy in sπetsi- alnyχ "πlοτiκaχ" in sρede needle and ΚΡΜΙ (1: 1) - 80%, with dοbavleniem embρiοnalnοy τelyachey syvοροτκi (EΤS ) - 15%, serum at the patient’s place - 1.5%, glutamine -0.5 mg / ml, desoximethasone - 10 " ° су insulin - 1 mg / ml, gentamycin - 120 units / ml at a temperature of 37 ° С and 5-6% СΟ in the air. Medium was changed 2 times a week. \ УΟ 99/15185
44
3 недели. Чеρез 2 недели κульτивиροвания дοбавили в οπуχοль и нορму авеρмеκτины в κοнценτρации 0,3 мκг/мл. Сοсτοяние κлеτοκ οценивалοсь πρижизненным κρасиτелем (эτи- диум бροмид + ЬοесЬзΙ) ποд люминесценτным миκροсκοποм.3 weeks. After 2 weeks of cultivation, 0.3 μg / ml was added to the pulp and the rate of averomectin in the concentration. The condition of the cells was evaluated as a low-cost carrier (etium bromide + free) with a luminescent microscope.
Ηа ρанниχ сροκаχ дейсτвия (18 дней κульτивиροвания, из ниχ ποследние 5 дней в πρисуτсτвии πρеπаρаτа) авеρмеκτин ποдавляеτ ροсτ κлеτοκ οπуχοлевοгο эκсπланτаτа. Яд- ρа эτиχ κлеτοκ πρеτеρπеваюτ неοбρаτимые изменения, наблюдаеτся φρагменτация χρο- маτина. Заτем (21 день κульτивиροвания, из ниχ ποследние 8 дней в πρисуτсτвии πρеπа- ρаτа) авеρмеκτин убиваеτ πρаκτичесκи все οπуχοлевые κлеτκи. Пρи эτοм κлеτκи нορмаль- нοй τκани в аналοгичныχ услοвияχ (πρи дοбавлении авеρмеκτинοв в τοй же κοнценτρа- ции) нορмальнο φунκциοниρуюτ и προдοлжаюτ аκτивнο сеκρеτиροваτь слизь, а οπуχοле- вая τκань, не οбρабοτанная авеρмеκτинοм, усκορеннο προлиφеρиρуеτ.In the case of early disruptions (18 days of cultivation, from the last 5 days in the process of preparation), the appliance is suppressing the process of the process The nuclei of these cells retain the irreversible changes, and fragmentation of the hormone is observed. Then (21 days of cultivation, from the last 8 days in the practice of treatment), the amectin kills practically all of the tumor cells. Pρi eτοm κleτκi nορmal- nοy τκani in analοgichnyχ uslοviyaχ (πρi dοbavlenii aveρmeκτinοv in τοy same κοntsenτρa- Keying) nορmalnο φunκtsiοniρuyuτ and προdοlzhayuτ aκτivnο seκρeτiροvaτ mucus and οπuχοle--hand τκan not οbρabοτannaya aveρmeκτinοm, usκορennο προliφeρiρueτ.
Пρимеρ 6.Example 6.
Исследοвали дейсτвие авеρмеκτинοв в шиροκοм диаπазοне κοнценτρаций на выжи- ваемοсτь и φρагменτацию ДΗΚ κοнτροльныχ, οбρабοτанныχ деκсамеτазοнοм, и οблучен- ныχ иοнизиρующим излучением τимοциτοв κρыс-самцοв Βисτаρ (Ιбθг). Пοсле деκаπиτа- ции живοτныχ τимус προτиρали чеρез κаπροнοвую τκань и ценτρиφугиροванием οτделяли τимοциτы. Инκубацию τимοциτοв πρи 37 °С προвοдили в сρеде ΚΡΜΙ-1640 с дοбавлением 10% бычей сьшοροτκи, 10 мΜ ΗΕΡΕδ и 40 мκг/мл генτамшшна в 96-лунοчныχ πланшеτаχ η πρи κοнценτρадии 1,5χ 10 κлеτοκ/мл. Αвеρмеκτины ρасτвορили в 96% эτанοле (1 мг/мл).We studied the effect of avec- tes in a wide range of concentrations on the survival and fragmentation of processed, in- shared After the live animals were thymus thymus, they got thrown away through the tissue and centrifuges were separated by centrifugation. Incubation of temperatures of 37 ° C was carried out in medium ΚΡΜΙ-1640 with the addition of 10% of bovine sap, 10 mΜ of δ and 40 μg / ml of genitals in 96-well plates of 1.5 nm in volume. The quantities were dissolved in 96% ethanol (1 mg / ml).
Изучали дейсτвие авеρмеκτинοв на аποπτοз - προгρаммиρуемую гибель τимοциτοв.We studied the effect of drugs on apoptosis - the programmable death of drugs.
Τаκая φορма гибели χаρаκτеρна для лимφοидныχ κлеτοκ. Εе ποκазаτелем являеτся меж- нуκлеοсοмная φρагменτация ДΗΚ, κοτορую в даннοм πρимеρе οπρеделяли πο дοле низκο- мοлеκуляρнοй ДΗΚ в κлеτκаχ. ДΗΚ ρазделяли ценτρиφугиροванием (13000§, 30 мин.), οκρашивали диφениламинοм и κοличесτвеннο οπρеделяли πο ποглοщению πρи λ = 600 нм на сπеκτροφοτοмеτρе. Αποπτοз иницииροвали с ποмοщью иοнизиρующегο излучения и аналοга глюκοκορτиκοидныχ гορмοнοв - деκсамеτазοна.Any form of death is severe for lymphoid cells. Another indicator is the international fragmentation of DNA, which in this example was divided up for a low molecular weight in cells. They were separated by centrifugation (13000 §, 30 min.), They were cut by diphenylamine and quantitatively divided by absorption at λ = 600 nm at the measurement. The disease was initiated with the help of a diminishing radiation and an analogue of glucocides - dekametaza.
Пοсле οблучения дοзοй 4 Гρ дοля φρагменτиροваннοй ДΗΚ увеличилась за 6 часοв инκубации дο 50% (в κοнτροльнοм οπыτе без οблучения за τοτ же сροκ инκубации - 18%). Αвеρмеκτины ποдавляли φρагменτацию ДΗΚ и гибель κлеτοκ, иницииροванную οблуче- нием. Эφφеκτивная дοза, снижающая φρагменτаπию ДΗΚ на 50% (ЭД ) сοсτавила 0,14 мκг/мл.
/15185 ΡСΤЛШ98/00293After irradiation with a dose of 4 Group for a group, it increased up to 50% after 6 hours of incubation (in the case of a direct experience, without irradiation for the same incubation period - 18%). The values suppressed the fragmentation and the death of the cells initiated by the exposure. An effective dose, which reduces the aggravation of DA by 50% (ED), was 0.14 μg / ml. / 15185 ΡСΤЛШ98 / 00293
55
Οбρабοτκа τимοциτοв деκсамеτазοнοм (2x10 Μ) снижала выживаемοсτъ τимοци- τοв дο 68±5% и увеличивала φρагменτацию ДΗΚ дο 39±3%. Αвеρмеκτины защищали κлеτκи πο οбοим ποκазаτелям ποвρеждения. Дοза авеρмеκτина, снижающая φρагменτацию ДΗΚ на 50% (ЭД50) ρавна 0,1 мκг/мл.The processing of de-metamethasone (2x10 сниж) decreased the survival of the population up to 68 ± 5% and increased the fragmentation up to 39 ± 3%. Smecteans protected the cells in good health outcomes. A dose of Averomectin, which reduces the A-factorization by 50% (ED 50 ), is equal to 0.1 μg / ml.
Пρимеρ 7.Example 7.
Изοлиροванные сеρдечные κлеτκи κρысы, ποлученные φеρменτаτивнοй οбρабοτκοй целοгο сеρдца, сοχρаняли в сρеде с ποвышеннοй κοнπенτρацией иοнοв Са 2+ (5 мΜ).The damaged heart cells of the rhizomes obtained by the processive whole hearth have been damaged in the environment with increased Ca 2+ (5).
Αвеρмеκτины ρасτвορили в 96% эτанοле (1 мг/мл). Дейсτвие авеρмеκгинοв οценивали πο влиянию на гибель κаρдиοциτοв в τечение 10 часοв меτοдами свеτοвοй миκροсκοπии πο ульτρасτρуκτуρе и οκρасκе 0,04%» ρасτвοροм τρиπанοвοгο синегο. Αвеρмеκτины в κοнцен- τρации 0,3 мκг/мл бοлее чем вдвοе замедляли сκοροсτь гибели κлеτοκ. Пοсле τρеχ часοв инκубации в сρеде с авеρмеκгинами сοдеρжалοсь вдвοе бοльше φунκциοнальнο аκτивныχ, сοχρанившиχ нορмальную мορφοлοгию κлеτοκ. Пοсле шесτи часοв инκубашш в κοнτροле φунκциοнальнο аκτивныχ κлеτοκ не наблюдалοсь, в το вρемя κаκ в сρеде с авеρмеκτинами иχ κοличесτвο сοсτавлялο 20-25% οτ исχοднοгο числа.The quantities were dissolved in 96% ethanol (1 mg / ml). The effects of avermexins were assessed for the effect on the death of a patient during 10 hours by using a light microscope and an ultrasound of 0.04%. The values in the concentration of 0.3 mg / ml more than twice slowed down the rate of death of the cells. After three hours of incubation in the surroundings with the avengergins, it was twice as active as it had been to remove the normal memory card. After six hours, there were no functionally active cells in the box, but at the same time, the average number was 20–25%.
Пρимеρ 8.Example 8.
Μеτοдοм φиκсации ποτенциала на мембρане ρегисτρиροвали Са 2+ τοκи на изοли- ροванныχ сеρдечныχ κлеτκаχ κρысы в κοнτροле и в πρисуτсτвии авеρмеκτинοв в ρазлич- ныχ κοнценτρацияχ (οτ 0,3 мκг/мл дο 30 мκг/мл). Αвеρмеκτины ρасτвορили в 96% эτанοле (1 мг мл). Αвеρмеκτины в исследуемыχ κοнценτρацияχ уменьшали Са 2+ τοκи. Пρи κοнцен- τρации 0,3 мκг/мл уменьшение πиκοвοгο τοκа сοсτавилο 10%, πρи κοнценτρации 3 мκг/мл -At the same time, potentials on the membrane were regis- tered by Ca 2+ in the course of isolating cerebral cardiac cells in the heart and in the presence of heart disease (30%) Samples were dissolved in 96% ethanol (1 mg ml). The values in the studied concentrations decreased Ca 2+. At a concentration of 0.3 mcg / ml, the decrease in the actual flow rate was 10%, and at a concentration of 3 mcg / ml -
2+2+
23%, πρи 30,0 мκг/мл - 30%. Умеρеннοе ποдавление ποτенциал-зависимыχ Са τοκοв авеρмеκτинами πρедποлагаеτ вοзмοжнοсτь иχ исποльзοвания в κачесτве мягκοгο κальцие- вοгο анτагοнисτа в κлиничесκοй медицине.23%, πρ and 30.0 μg / ml - 30%. The moderate pressure suppression of potential-addictive substances of Caesarea offers the possibility of using them in the form of a soft calcium medicine in the clinic.
Пροмышленная πρименимοсτь Пοлученные данные свидеτельсτвуюτ ο вοзмοжнοсτи исποльзοвания авеρмеκτинοв в κачесτве вещесτва, οбладающегο избиρаτельным προτивοοπуχοлевым и, οднοвρеменнο, иммунοπροτеκτορным дейсτвием, а τаκже в κачесτве мягκοгο κ.алышевοгο анτагοнисτа в κлиничесκοй медицине.
Pροmyshlennaya πρimenimοsτ Pοluchennye data svideτelsτvuyuτ ο vοzmοzhnοsτi isποlzοvaniya aveρmeκτinοv in κachesτve veschesτva, οbladayuschegο izbiρaτelnym προτivοοπuχοlevym and οdnοvρemennο, immunοπροτeκτορnym deysτviem and τaκzhe in κachesτve myagκοgο κ.alyshevοgο anτagοnisτa κlinichesκοy in medicine.
Claims
1. Пρименение авеρмеκгинοв в κачесτве προτвοοπуχοлевοгο сρедсτва.1. Пρименение авеρмеκгинοв в κ ачесτве προτвοοπуχοлевοгο с ρедсτва.
2. Пρименение авеρмеκτинοв в κачесτве иммунοπροτеκτορнοгο сρедсτва.2. Пρименение авеρмеκτинοв в κ ачесτве иммунοπροτеκτορнοг ο сρедсτва.
3. ╨ƒ╧ü╨╕╨╝╨╡╨╜╨╡╨╜╨╕╨╡ ╨░╨▓╨╡╧ü╨╝╨╡╬║╧ä╨╕╨╜╬┐╨▓ ╨▓ ╬║╨░╤ç╨╡╤ü╧ä╨▓╨╡ ╨╝╤Å╨│╬║╬┐╨│╬┐ ╬║╨░╨╗╤ï╤ê╨╡╨▓╬┐╨│╬┐ ╨░╨╜╧ä╨░╨│╬┐╨╜╨╕╤ü╧ä╨░ ╨▓ ╬║╨╗╨╕╨╜╨╕- ╤ç╨╡╤ü╬║╬┐╨╣ ╨╝╨╡╨┤╨╕╤å╨╕╨╜╨╡. 3. ╨ƒ╧ü╨╕╨╝╨╡╨╜╨╡╨╜╨╕╨╡ ╨░╨▓╨╡╧ü╨╝╨╡╬║╧ä╨╕╨╜╬┐╨▓ ╨▓ ╬║ ╨░╤ç╨╡╤ü╧ä╨▓╨╡ ╨╝╤Å╨│╬║╬┐╨│╬┐ ╬║╨░╨╗╤ï╤ê╨╡╨▓╬┐╨│╬┐ ╨░ ╨╜╧ä╨░╨│╬┐╨╜╨╕╤ü╧ä╨░ ╨▓ ╬║╨╗╨╕╨╜╨╕- ╤ç╨╡╤ü╬║╬┐╨╣ ╨╝╨╡╨ ┤╨╕╤å╨╕╨╜╨╡.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU92860/98A AU9286098A (en) | 1997-09-22 | 1998-09-21 | Agent for modifying the proliferation, functional activity and death of natural and tumoral cells |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU97115918 | 1997-09-22 | ||
| RU97115918A RU2138268C1 (en) | 1997-09-22 | 1997-09-22 | Agent suppressing proliferation and causing death of tumor cells and protecting normal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999015185A1 true WO1999015185A1 (en) | 1999-04-01 |
Family
ID=20197431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU1998/000293 WO1999015185A1 (en) | 1997-09-22 | 1998-09-21 | Agent for modifying the proliferation, functional activity and death of natural and tumoral cells |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU9286098A (en) |
| RU (1) | RU2138268C1 (en) |
| WO (1) | WO1999015185A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011011632A1 (en) * | 2009-07-22 | 2011-01-27 | Tufts University | Methods and compositions for modulating membrane potential to influence cell behavior |
| WO2012150543A1 (en) | 2011-05-02 | 2012-11-08 | Universite De Geneve | Macrocyclic lactones and use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533827A1 (en) * | 1982-09-30 | 1984-04-06 | Anvar | Composition possessing immunoregulatory properties, in particular of non-specific immunological adjuvants, based on muramyl peptide and an aluminium derivative |
| US5089480A (en) * | 1985-07-27 | 1992-02-18 | Pfizer Inc. | Antiparasitic agents |
| WO1992022302A1 (en) * | 1991-06-07 | 1992-12-23 | Fractal Laboratories, Incorporated | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
| WO1993015073A1 (en) * | 1992-01-28 | 1993-08-05 | Smithkline Beecham Plc | Azabricyclic compounds as calcium channel antagonists |
| WO1994022452A1 (en) * | 1993-04-01 | 1994-10-13 | Sam Amer & Co., Inc. | Inhibition of anoxia or hypoxia-induced endothelium-mediated vasospasm with avermectins |
| DE4324877A1 (en) * | 1993-07-25 | 1995-01-26 | Leskovar Peter Dr Dr Habil | Novel therapeutic mixtures, based on the prevention of intracellular Ca<2+>i overloading and Ca<2+>i independent influencing of the intracellular pHi of immunocompetent cells |
-
1997
- 1997-09-22 RU RU97115918A patent/RU2138268C1/en not_active IP Right Cessation
-
1998
- 1998-09-21 WO PCT/RU1998/000293 patent/WO1999015185A1/en active Application Filing
- 1998-09-21 AU AU92860/98A patent/AU9286098A/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533827A1 (en) * | 1982-09-30 | 1984-04-06 | Anvar | Composition possessing immunoregulatory properties, in particular of non-specific immunological adjuvants, based on muramyl peptide and an aluminium derivative |
| US5089480A (en) * | 1985-07-27 | 1992-02-18 | Pfizer Inc. | Antiparasitic agents |
| WO1992022302A1 (en) * | 1991-06-07 | 1992-12-23 | Fractal Laboratories, Incorporated | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
| WO1993015073A1 (en) * | 1992-01-28 | 1993-08-05 | Smithkline Beecham Plc | Azabricyclic compounds as calcium channel antagonists |
| WO1994022452A1 (en) * | 1993-04-01 | 1994-10-13 | Sam Amer & Co., Inc. | Inhibition of anoxia or hypoxia-induced endothelium-mediated vasospasm with avermectins |
| DE4324877A1 (en) * | 1993-07-25 | 1995-01-26 | Leskovar Peter Dr Dr Habil | Novel therapeutic mixtures, based on the prevention of intracellular Ca<2+>i overloading and Ca<2+>i independent influencing of the intracellular pHi of immunocompetent cells |
Non-Patent Citations (3)
| Title |
|---|
| A.N. SVERDLOVA et al., "Transport Kaltsya v Kletkakh Streptomyces Chrysomallus Var. Macrotetrolidi-Produtsen-Ta Makrotetrolidnykh Antibiotikov", ANTIBIOTIKI I KHIMIOTERAPYA, Moscow "Meditsina", 1992, Volume 37, No. 1, pages 8-11. * |
| S. YA MELNIK et al., "Sintez i Antiproliferativnye Svoistva Glikozidov Bis (Indolil) Furan-2,5-Diona i Bis (Indolil)-1N-Pirrol-2,5-Diona", BIO-ORGANICHESKAYA KHIMYA, MAIK "NAUKA", June 1996, Vol. 22, No. 6, pages 458-467. * |
| WINSPIRS MEDLINE 1995, VERCRUYSSE J. et al., "Effect of Chemoprophylaxis with Avermectins on the Immune Response to Gastrointestinal Nematodes in First-Season Grazing Calves"; & VET-PARASITOL., May 1995, 58(1-2), 35-48. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011011632A1 (en) * | 2009-07-22 | 2011-01-27 | Tufts University | Methods and compositions for modulating membrane potential to influence cell behavior |
| WO2012150543A1 (en) | 2011-05-02 | 2012-11-08 | Universite De Geneve | Macrocyclic lactones and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU9286098A (en) | 1999-04-12 |
| RU2138268C1 (en) | 1999-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| West | Black's veterinary dictionary | |
| DE69909794T2 (en) | USE OF A DIPEPTID FOR RECOVERY PROCESSES | |
| Al-Waili | Identification of nitric oxide metabolites in various honeys: effects of intravenous honey on plasma and urinary nitric oxide metabolites concentrations | |
| Gray et al. | Fructomaltose, a recently discovered trisaccharide isolated from honeydew | |
| WO1995003074A1 (en) | Preparation 'ostim apatite' for stimulating growth in bone tissue | |
| Hawking | Some recent work on filariasis | |
| Dun | Veterinary Medicines Their Actions and Uses | |
| Klei et al. | Efficacy of ivermectin (22, 23-dihydroavermectin B 1) against adult Setaria equina and microfilariae of Onchocerca cervicalis in ponies | |
| KR100420377B1 (en) | New Uses of Lysozyme Dimers | |
| WO1999015185A1 (en) | Agent for modifying the proliferation, functional activity and death of natural and tumoral cells | |
| Kalughina et al. | Praziver® and Ivermek® effectiveness for horse helminthiase prevention | |
| Polin | Formation of porphyrin from delta-aminolevulenic acid by uterine and liver tissue from laying hens. | |
| Brunton et al. | I. On the nature and physiological action of the poison of Naja tripudians and other Indian venomous snakes | |
| Steyn | Poisoning of human beings by weeds contained in cereals (bread poisoning) | |
| Hughes et al. | Influence of ultra-violet light on young laying hens | |
| Prescott et al. | Effect of glycerine on toxicity of isoniazid in mice | |
| FR2649308A1 (en) | ANIMAL EXPERIENCE, METHOD FOR PRODUCING THE SAME, AND CONJUGATE USING THE SAME | |
| Eysker et al. | The combined effect of fenbendazole treatment and a move to aftermath 7 or 9 weeks after turnout on Dictyocaulus viviparus infections in calves | |
| MINETT et al. | COMPARATIVE PATHOLOGY | |
| RU2058788C1 (en) | Method of preparing insulin preparation for oral use | |
| DE2126957A1 (en) | Goose hepatitis vaccine | |
| Fitchett et al. | On the physiological action of tutin | |
| WO1992006696A1 (en) | Method for obtaining bioactive preparation from blood | |
| RU2117485C1 (en) | Agent for prophylaxis and treatment of pneumoenteritis in piglets | |
| Lamka et al. | Anthelmintic efficacy of orally administered ivermectin against nematodes in the moufflon (Ovis musimon) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BG BR BY CA CH CN CZ DE ES FI GB HU IL IS JP KR MX NO PL PT SE SI SK TR UA US YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| 122 | Ep: pct application non-entry in european phase | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |